We continue to monitor the unfolding global impact of COVID-19, and as the world evolves, so do we. We are transforming this event to be fully digital.
Biologics continue to develop into the most important group of medical drugs in the future. The market share value is steadily growing, new therapeutic approaches offer new possibilities to more successful treatment of severe diseases.
ISPE will continue the series of successful biotechnology conferences featuring the 2020 ISPE Biotechnology Conference. Case studies will be presented, from concepts to industrialisation. Plant tours to new, state-of-the-art facilities will be offered, and the conference will be followed by a workshop where current industry practise and new ways of operations, e.g.
In particular, the group of Advanced Therapy Medicinal Products (ATMPs) have particular GMP regulations linked to Annex 2 from PIC/S. “How to ensure that the GMP requirements for the manufacturing of biologics are met?” is one of the most important questions asked when companies invest in manufacturing facilities. The conference will highlight the differences between EC GMP Guide and the Annex 2 from PIC/S.
New technology platforms and the wave of digitisation will open innovative ways for process analysis, process verification and overall process control. The ISPE Pharma 4.0 approach will demonstrate elements and enablers but also roadmaps for implementation in biological manufacturing.
Data science - and process science concepts are key enablers for stable processes and a premise for continuous product supply. The conference will focus on how this can be successfully achieved.
Professionals at all levels of the pharmaceutical industry including:
Young Professionals Senior Executives Communities of Practice Special Interest Groups Equipment and Services Suppliers Regulatory Professionals